The pharmaceutical company will reapply in 2025.
发布者：BY MARKETWIRE，转转请注明出处：https://robotalks.cn/novo-nordisk-withdraws-application-for-wegovy-within-cardiovascular-disease/
Novo Nordisk withdraws application for Wegovy within cardiovascular disease
赞 (0)
关于作者
Novo Nordisk reports 25% sales increase, upgrades full-year guidance
上一篇
11 8 月, 2024 1:24 下午
GLP-1 sales accounted for 75% of Novo Nordisk’s Q2 revenues
下一篇
11 8 月, 2024 1:24 下午
相关推荐
-
E3 Lithium Files Third Quarter 2024 Financial Statements and MD&A
CALGARY, Alberta–( ORGANIZATION CORD)– $EEMMF #canadianenergy– E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), “E3 Lithium” or the “Firm,…
-
U.S. Dept. of Commerce Unveils Supply Chain Risk Assessment Tool
range enables the united state to evaluate supply chain threat throughout the economic climate, and after that gives an extensive analysis analysis of what’s driving those pr…
-
Foxconn Trains Robots, Streamlines Assembly With NVIDIA AI and Omniverse
Foxconn runs greater than 170 manufacturing facilities around the globe– the current one a digital plant pressing the modern in commercial automation. It’s the electron…
-
Meta’s AI-powered smart glasses raise concerns about privacy and user data
Ray-Ban Meta smart glasses are just one of many wearable tech devices on the market. The glasses, which first launched in 2021, are a collaboration between Meta and Italian-French …
-
“AAM Institute Announces Successful Conclusion of Two Day GAAMF Event”
The Superior Air Mobility (AAM) Institute introduced this week that its two day International Superior Air Mobility Discussion board (GAAMF), held on July twenty ninth and thirtiet…
